Octreótido Sandoz (Octreotide Acetate)

Octreotide acetate, the active ingredient in Octreótido Sandoz, is a somatostatin analog presented as a sterile solution for intravenous and subcutaneous use. It is employed to control hormone‑related disorders such as acromegaly, carcinoid syndrome diarrhea, and VIPoma in adult patients.

GNH USA supplies Octreótido Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Octreótido Sandoz is a somatostatin analog used to manage conditions driven by excess hormone secretion. - Acromegaly: reduces growth hormone levels and controls disease activity. - Carcinoid syndrome associated diarrhea: decreases serotonin‑mediated intestinal secretions and improves stool frequency. - Vasoactive intestinal peptide tumor (VIPoma): suppresses VIP release, alleviating watery diarrhea and electrolyte loss. - Prevention of postoperative pancreatic fistula: limits pancreatic exocrine secretion to reduce fistula formation.

Common Side Effects: - Nausea: mild to moderate discomfort in the stomach. - Abdominal pain or cramps: transient gastrointestinal upset. - Diarrhea or constipation: changes in bowel habits. - Injection site reactions: redness, swelling, or bruising. - Hyperglycemia: elevated blood glucose, especially in diabetic patients. - Gallstone formation: biliary sludge or stones with prolonged therapy.

Serious or Rare Side Effects: - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe hyperglycemia or hypoglycemia: requires immediate medical attention. - Bradycardia or arrhythmias: slow heart rate or irregular rhythm. - Anaphylactic reactions: hives, swelling, or breathing difficulty. - Hepatic dysfunction: jaundice or abnormal liver tests.

Octreótido Sandoz requires careful monitoring and specific precautions before and during therapy. - Monitor glucose levels: patients with diabetes may experience hyperglycemia or hypoglycemia. - Assess cardiac function: bradycardia or conduction abnormalities can occur. - Evaluate gallbladder status: long‑term use may promote gallstone formation. - Use caution in hepatic impairment: adjust monitoring as liver metabolism may be affected. - Avoid abrupt discontinuation: sudden withdrawal can lead to rebound hormone secretion. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreótido Sandoz may interact with several drug classes, requiring attention to avoid adverse outcomes. Major Interactions (Avoid): - Cyclosporine: may increase octreotide plasma concentrations. - Quinidine: combined use can precipitate cardiac arrhythmias. - Other somatostatin analogs: additive hormonal suppression may lead to severe side effects. Moderate Interactions (Monitor Closely): - Glucocorticoids: may alter glucose control; monitor blood sugar. - Antidiabetic agents: adjust dosing as octreotide can affect insulin and glucagon levels. - Antihypertensives: blood pressure may fluctuate; observe hemodynamic response.